Does Medicare cover tirzepatide for weight loss?
A coverage page written to our verification standard: the statute is a fact, the demonstration terms are reported, and the cash fallbacks are verified rows in the dataset.
As of August 31, 2026:
Since July 1, 2026, eligible Medicare Part D enrollees are reported to pay a $50 monthly copay for the Zepbound KwikPen under the CMS GLP-1 Bridge demonstration, reported to run through December 31, 2027 with prior authorization required. Reported eligibility: BMI 35 or higher; or 30 or higher with chronic kidney disease, HFpEF or uncontrolled hypertension; or 27 or higher with prediabetes or established cardiovascular disease. Reported exclusions: Zepbound vials and single-dose pens are not covered, and the $50 does not count toward the Part D deductible or the annual out-of-pocket cap. Outside the demonstration, Part D remains barred by statute from covering drugs prescribed for weight loss. We have not verified these program terms first-party; confirm them with Medicare or the plan before relying on them. The verified cash fallback in our dataset is LillyDirect vials at $299–$449 per month by dose (verified August 25, 2026, grade B).
The statute first
Medicare Part D has been barred by statute from covering drugs prescribed for weight loss since the benefit was created; that exclusion is why “does Medicare cover Zepbound” had a one-word answer for years. What changed in 2026 is a time-limited CMS demonstration layered on top of the statute, not a repeal of it.
The GLP-1 Bridge, as reported
Since July 1, 2026, eligible Medicare Part D enrollees are reported to pay a $50 monthly copay for the Zepbound KwikPen under the CMS GLP-1 Bridge demonstration, reported to run through December 31, 2027 with prior authorization required. Reported eligibility: BMI 35 or higher; or 30 or higher with chronic kidney disease, HFpEF or uncontrolled hypertension; or 27 or higher with prediabetes or established cardiovascular disease. Reported exclusions: Zepbound vials and single-dose pens are not covered, and the $50 does not count toward the Part D deductible or the annual out-of-pocket cap.
We have not verified these program terms first-party; confirm them with Medicare or the plan before relying on them. Basis: CMS demonstration terms as described in CMS materials and dated third-party trackers.
If the Bridge does not apply to you
The verified cash routes are the ones this site ranks: LillyDirect vials at $299–$449 per month by dose (verified August 25, 2026, grade B), and the compounded market from $125 per month on a verified plan — see the cheapest way to get tirzepatide and the compounded ranking. Compounded tirzepatide is not an FDA-approved product; Zepbound is.
Semaglutide and Medicare
The same statutory exclusion applies to weight-loss semaglutide (Wegovy). Where semaglutide is prescribed for a covered indication, coverage is a plan-level question we do not track; the verified cash routes are on the Wegovy price page and the compounded semaglutide ranking.
Definitions used on this page
Questions this page answers
Does Medicare cover Zepbound in 2026?
Since July 1, 2026, eligible Medicare Part D enrollees are reported to pay a $50 monthly copay for the Zepbound KwikPen under the CMS GLP-1 Bridge demonstration, reported to run through December 31, 2027 with prior authorization required. Reported eligibility: BMI 35 or higher; or 30 or higher with chronic kidney disease, HFpEF or uncontrolled hypertension; or 27 or higher with prediabetes or established cardiovascular disease. Reported exclusions: Zepbound vials and single-dose pens are not covered, and the $50 does not count toward the Part D deductible or the annual out-of-pocket cap. Outside the demonstration, Part D remains barred by statute from covering drugs prescribed for weight loss. We have not verified these program terms first-party; confirm them with Medicare or the plan before relying on them. The verified cash fallback in our dataset is LillyDirect vials at $299–$449 per month by dose (verified August 25, 2026, grade B).
Does the $50 Bridge copay count toward my deductible?
As reported, no — the demonstration copay is described as sitting outside the Part D deductible and the annual out-of-pocket cap. That is a reported term we have not verified; confirm it with Medicare or the plan.
Which Zepbound format does the Bridge cover?
As reported, only the KwikPen; vials and single-dose pens are described as excluded. Confirm with the plan before filling.